-+ 0.00%
-+ 0.00%
-+ 0.00%

Lenz Therapeutics Reports 110,000 VIZZ Prescriptions Since Launch

PUBT·10/28/2026 23:18:46
Listen to the news
Lenz Therapeutics Reports 110,000 VIZZ Prescriptions Since Launch
  • Lenz Therapeutics reported 50% quarter-over-quarter growth in Q3 2026, with VIZZ reaching 110,000 total prescriptions since launch.
  • Cash totaled approximately $197 million as of Q3 2026.
  • Eleven international regulatory applications are under review, with the first approval anticipated as early as Q4 2026.
  • Up to five international regulatory approvals are expected by the end of 2027.
  • VIZZ has eight granted US patents extending up to 2044, with US new chemical entity regulatory exclusivity through 2030.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lenz Therapeutics Inc. published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.